CD274 and cancer: The interaction between PD-1/PD-L1 inhibitors and CAR T-cell treatment offers a promising technique for enhancing CAR T-cell effectiveness, potentially reducing the immunosuppressive tumor microenvironment and CAR T-cell fatigue, so opening the path for improved responses in a variety of cancers (148).